Literature DB >> 25351518

Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues.

Trevor J Pitcher1, Vanessa V Sarathy1, Kiyohiko Matsui1, Gregory D Gromowski1, Claire Y-H Huang2, Alan D T Barrett1.   

Abstract

The dengue virus (DENV) envelope protein domain 3 (ED3) is the target of potent virus neutralizing antibodies. The DENV-2 ED3 contains adjacent type-specific and DENV complex-reactive antigenic sites that are composed of a small number of residues that were previously demonstrated to be critical for antibody binding. Site-directed mutagenesis of a DENV-2 16681 infectious clone was used to mutate critical residues in the DENV-2 type-specific (K305A and P384A) and DENV complex-reactive (K310A) antigenic sites. The K305A mutant virus multiplied like the parent virus in mosquito and mammalian cells, as did the P384A mutant virus, which required a compensatory mutation (G330D) for viability. However, the K310A mutant virus could not be recovered. The DENV-2 type-specific critical residue mutations K305A and P384A+G330D reduced the ability of DENV-2 type-specific, but not DENV complex-reactive, mAbs to neutralize virus infectivity and this was directly correlated with mAb binding affinity to the rED3 mutants.
© 2015 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25351518      PMCID: PMC4298678          DOI: 10.1099/vir.0.070813-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

2.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 3.  Flavivirus genome organization, expression, and replication.

Authors:  T J Chambers; C S Hahn; R Galler; C M Rice
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

4.  Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.

Authors:  K Hiramatsu; M Tadano; R Men; C J Lai
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

5.  Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion.

Authors:  John T Roehrig; Siritorn Butrapet; Nathan M Liss; Susan L Bennett; Betty E Luy; Thomas Childers; Karen L Boroughs; Janae L Stovall; Amanda E Calvert; Carol D Blair; Claire Y-H Huang
Journal:  Virology       Date:  2013-04-06       Impact factor: 3.616

6.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

7.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Whitney E Purtha; Theodore Oliphant; Grant E Nybakken; Jacob J Schlesinger; John T Roehrig; Gregory D Gromowski; Alan D Barrett; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kelly J Moss; Thomas Childers; Steven M Erb; Amanda E Calvert; Shawn J Silengo; Richard M Kinney; Carol D Blair; John T Roehrig
Journal:  Virology       Date:  2009-11-12       Impact factor: 3.616

10.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Adamberage R de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Kristie D Ibarra; Jiaqi Wang; Eva Harris; Aravinda de Silva; James E Crowe; Shee-Mei Lok
Journal:  EMBO Mol Med       Date:  2014-01-13       Impact factor: 12.137

View more
  8 in total

1.  Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.

Authors:  Ashlie Thomas; Devina J Thiono; Stephan T Kudlacek; John Forsberg; Lakshmanane Premkumar; Shaomin Tian; Brian Kuhlman; Aravinda M de Silva; Stefan W Metz
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

2.  Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III.

Authors:  Guang-Hui Ji; Yong-Qiang Deng; Xiao-Jie Yu; Tao Jiang; Hua-Jing Wang; Xin Shi; Da-Peng Zhang; Xiao-Feng Li; Shun-Ya Zhu; Hui Zhao; Jian-Xin Dai; Cheng-Feng Qin; Ya-Jun Guo
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

3.  Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.

Authors:  Stefan W Metz; Shaomin Tian; Gabriel Hoekstra; Xianwen Yi; Michelle Stone; Katie Horvath; Michael J Miley; Joseph DeSimone; Chris J Luft; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2016-10-20

Review 4.  Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective.

Authors:  So Young Kim; Bing Li; Robert J Linhardt
Journal:  Pharmaceuticals (Basel)       Date:  2017-05-04

5.  Oligomeric state of the ZIKV E protein defines protective immune responses.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; John Forsberg; Michael J Miley; Cesar A Lopez; Helen M Lazear; Shaomin Tian; Aravinda M de Silva
Journal:  Nat Commun       Date:  2019-10-10       Impact factor: 14.919

6.  In Silico Analysis of Dengue Virus Serotype 2 Mutations Detected at the Intrahost Level in Patients with Different Clinical Outcomes.

Authors:  Maria Celeste Torres; Ana Luiza Martins Karl; Matheus Müller Pereira da Silva; Laurent Emmanuel Dardenne; Ana Maria Bispo de Filippis
Journal:  Microbiol Spectr       Date:  2021-09-01

7.  Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.

Authors:  Stefan W Metz; Ashlie Thomas; Laura White; Mark Stoops; Markus Corten; Holger Hannemann; Aravinda M de Silva
Journal:  Virol J       Date:  2018-04-02       Impact factor: 4.099

8.  Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; Yi Xianwen; Michele Stone; Katie Horvath; Michael J Miley; Chris Luft; Joseph M DeSimone; Shaomin Tian; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2018-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.